# Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00306813** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Wuerzburg** · enrollment: 53 (estimated)

## Conditions studied

- Relapse
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Revlimid

## Key facts

- **NCT ID:** NCT00306813
- **Lead sponsor:** University of Wuerzburg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2009-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306813, "Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00306813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*